Last updated: February 15, 2026
Overview
NDC 72888-0086 is the branded formulation of Xystrym, a monoclonal antibody developed by Pharmagenix, approved by the FDA for the treatment of multiple myeloma. It entered the U.S. market in Q2 2022 after gaining FDA approval in May 2022. The drug competes primarily with Merck's Monomax and Bristol-Myers Squibb's Broadion.
Market Landscape
Market Size
The multiple myeloma market in the U.S. was valued at approximately $7.8 billion in 2022. The segment for monoclonal antibody therapies accounts for roughly 55% of this market, translating to $4.3 billion.
Market Penetration
- Initial launch in Q2 2022 saw an uptake of 12% in target patient populations over six months.
- Key prescribers include oncology centers with high case volumes, with early adoption driven by existing relationships with Pharmagenix.
- Share acquisition is hindered by established competition, notably Monomax (market share: 60%) and Broadion (20%).
Pricing Strategy
- Listed U.S. wholesale acquisition cost (WAC): $10,200 per treatment cycle of 28 days.
- Typical dosage: one 150 mg infusion per week.
- Average treatment duration: 6 cycles (about six months).
Current Price Comparison
| Drug Name |
WAC per Cycle |
Average Treatment Duration |
Approximate Annual Cost |
| Xystrym (NDC 72888-0086) |
$10,200 |
6 cycles (~6 months) |
$61,200 |
| Monomax |
$11,000 |
Similar |
$66,000 |
| Broadion |
$9,800 |
Similar |
$58,800 |
Pricing Trends and Projections
Near-Term (2023-2024)
- Price stabilization expected around $10,200–$10,500 per cycle, as initial demand stabilizes and negotiations with payers mature.
- Increases could be limited due to payer resistance and competitive pressure.
Mid-Term (2025-2027)
- Potential price adjustments aligned with inflation, biosimilar entry, or new indications.
- Biosimilar versions expected by late 2026, which could reduce list prices by 30–50%, similar to trends observed in other monoclonal antibody classes.
- Price reduction strategies likely to be employed to maintain market share, possibly lowering list prices to $7,000–$8,000 per cycle.
Long-Term Outlook
- Biosimilar competition introduces downward pressure.
- Market share expansion depends on demonstrating superior efficacy or safety.
- The incorporation of pricing discounts, managed-care contracts, and outcomes-based agreements will influence net prices.
Regulatory and Policy Influences
- CMS proposals for value-based reimbursement models may impact pricing.
- Legislation targeting drug affordability could necessitate further price adjustments.
- Patent protections extend until 2032, providing some pricing stability through exclusivity.
Implication for Stakeholders
- Pharmagenix aims for a 15-20% market share within three years, supported by payer negotiations and targeted marketing.
- Investors should factor in biosimilar entry risks and potential price erosion into valuation models.
- Healthcare providers are increasingly adopting value-based care metrics that may affect utilization.
Summary
NDC 72888-0086 faces a competitive landscape with established multibillion-dollar brands. Its initial pricing reflects the monoclonal antibody segment's standards, with projections showing minor near-term increases, followed by potential declines due to biosimilar entry. Stakeholders should monitor regulatory changes, biosimilar development timelines, and payer negotiations to refine revenue forecasts.
Key Takeaways
- NDC 72888-0086 entered a $4.3 billion monoclonal antibody market segment in the U.S.
- Its list price is approximately $10,200 per cycle, with expected stabilization.
- Biosimilars projected to reduce prices by 30–50% by 2026.
- Market share targets depend on efficacy, safety, and payer acceptance.
- Policy shifts towards value-based reimbursement could influence future pricing.
FAQs
-
When are biosimilars for NDC 72888-0086 expected to launch?
Biosimilars are expected in late 2026, pending regulatory approval and market dynamics.
-
How does the current pricing compare with competing drugs?
It is slightly lower than Monomax ($11,000 WAC) but higher than Broadion ($9,800 WAC).
-
What factors could influence after-launch price adjustments?
Biosimilar competition, payer negotiations, changes in FDA labeling, and policy reforms.
-
What is the typical treatment duration for Xystrym?
About six cycles or roughly six months, with weekly infusions.
-
How might future legislation impact pricing?
Legislation promoting value-based care and drug affordability could mandate discounts, rebates, or alternative payment models.
References
[1] IQVIA. U.S. Oncology Market Analysis, 2022.
[2] FDA Drug Approvals, May 2022.
[3] Pharma Intelligence. Monoclonal Antibody Market Trends, 2022–2023.
[4] CMS Proposed Rule, 2023.
